Hims & Hers Health, Inc. (HIMS) is trading around $27.18 as of 3:30pm UTC on 2 February 2026, moving within an intraday range of approximately $26.49–$29.67 on Capital.com’s USD-denominated HIMS CFD feed. Past performance is not a reliable indicator of future results.

The stock is trading against a backdrop of recently reported Q3 2025 results, where Hims & Hers posted revenue of about $599 million, up roughly 49% year-on-year, alongside subscriber growth to nearly 2.5 million. These figures point to continued expansion of its direct-to-consumer telehealth model (Hims & Hers Health, 3 November 2025). Recent commentary has also highlighted ongoing discussions with Novo Nordisk over potential access to the weight-loss treatment…